Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01832480 · ClinicalTrials.gov registry record · Phase 3

Trichomonas Vaginalis Repeat Infections Among HIV Negative Women

A Phase 3 study, sponsored by Tulane University Health Sciences Center.

Completed
Registry status
Phase 3
Development phase
623
Enrollment target

NCT01832480: Completed Phase 3 study, sponsored by Tulane University Health Sciences Center.

NCT01832480 is a Phase 3 study that has completed, run by Tulane University Health Sciences Center. The registered enrollment target is 623 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01832480, a Phase 3 study, has completed, sponsored by Tulane University Health Sciences Center.

COMPLETED
Registry status
Phase 3
Development phase
623 participants
Enrollment target

Study Summary

The overall goal of this project is to determine the influence of patient treatment and host factors on repeat Trichomonas vaginalis (TV) infections among HIV-negative women

Primary Outcome

Presence of TV is assessed by nucleic acid amplification test (NAAT) of vaginal swab collected 4 weeks post treatment completion.

Interventions

  • DRUG MTZ 500 mg twice daily x 7 days
  • DRUG MTZ 2 g

Trial Details

FieldValue
Enrollment Target 623 participants
Start Date 2014-10-06
Est. Completion 2017-06-05
Phase Phase 3

What the finished NCT01832480 record still lists

NCT01832480 is an interventional study that assigns participants to a tested intervention. The registered 623 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower).

The record links to 0 conditions, and to 2 interventions - of which MTZ 500 mg twice daily x 7 days is the first listed.

NCT01832480 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01832480 about?

NCT01832480 is a clinical study titled "Trichomonas Vaginalis Repeat Infections Among HIV Negative Women". The overall goal of this project is to determine the influence of patient treatment and host factors on repeat Trichomonas vaginalis (TV) infections among HIV-negative women

What is the current status of trial NCT01832480?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 623 participants. The study started on 2014-10-06. Estimated completion is 2017-06-05.

What interventions are being tested in trial NCT01832480?

The interventions under investigation include: MTZ 500 mg twice daily x 7 days (DRUG), MTZ 2 g (DRUG).

Who is sponsoring clinical trial NCT01832480?

This trial is sponsored by Tulane University Health Sciences Center, which has 10 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01832480's enrollment target sits among peer trials

623 588th of 2000 higher than 1,413 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06406049 · 624 participants · NA

    Finishing HIV Project

  • NCT05349227 · 625 participants · NA

    Comprehensive Outcomes for After Cancer Health

  • NCT06103864 · 625 participants · Phase 3

    A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

  • NCT06230510 · 625 participants · NA

    Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01832480, the US trial registry maintained by the National Library of Medicine. NCT01832480 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.